The CEO of drug company AC Immune shared her thoughts on a recent failed tau vaccine trial, lessons learned, and what comes next. The…
Drugmaker Cassava believes its experimental Alzheimer’s therapy, which sent the company’s stock values surging with a recent phase 2 study announcement, could beat Biogen’s…
Now under review, the drug pimavanserin may become the first FDA-approved treatment for dementia-related psychosis. Roughly 2.4 million Americans experience symptoms of dementia-related psychosis,…
Biogen has announced new data behind the Alzheimer’s drug aducanumab suggests it was working on early stage patients. Jeff Borghoff was a participant for…